Ascendis Pharma Net Worth
Ascendis Pharma Net Worth Breakdown | ASND |
Ascendis Pharma Net Worth Analysis
Ascendis Pharma's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Ascendis Pharma's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Ascendis Pharma's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Ascendis Pharma's net worth analysis. One common approach is to calculate Ascendis Pharma's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Ascendis Pharma's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Ascendis Pharma's net worth. This approach calculates the present value of Ascendis Pharma's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Ascendis Pharma's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Ascendis Pharma's net worth. This involves comparing Ascendis Pharma's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Ascendis Pharma's net worth relative to its peers.
Enterprise Value |
|
To determine if Ascendis Pharma is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Ascendis Pharma's net worth research are outlined below:
| The company reported the previous year's revenue of 266.72 M. Net Loss for the year was (481.45 M) with profit before overhead, payroll, taxes, and interest of 271.75 M. | |
| Ascendis Pharma AS currently holds about 955.15 M in cash with (467.36 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 17.11. | |
| Over 99.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: Ascendis Pharma AS Stock Price Down 5.1 percent - Should You Sell - MarketBeat |
Ascendis Pharma Quarterly Good Will |
|
Ascendis Pharma uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Ascendis Pharma AS. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Ascendis Pharma's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 15th of February 2024 Upcoming Quarterly Report | View | |
| 25th of April 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 15th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Ascendis Pharma Target Price Consensus
Ascendis target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Ascendis Pharma's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 15 | Strong Buy |
Most Ascendis analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Ascendis stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Ascendis Pharma AS, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationAscendis Pharma Target Price Projection
Ascendis Pharma's current and average target prices are 128.13 and 189.53, respectively. The current price of Ascendis Pharma is the price at which Ascendis Pharma AS is currently trading. On the other hand, Ascendis Pharma's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Ascendis Pharma Market Quote on 18th of January 2025
Target Price
Analyst Consensus On Ascendis Pharma Target Price
Know Ascendis Pharma's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Ascendis Pharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Ascendis Pharma AS backward and forwards among themselves. Ascendis Pharma's institutional investor refers to the entity that pools money to purchase Ascendis Pharma's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Wellington Management Company Llp | 2024-09-30 | 1.3 M | Amvescap Plc. | 2024-09-30 | 1.2 M | Camber Capital Management Llc | 2024-09-30 | 700 K | Ameriprise Financial Inc | 2024-09-30 | 669.7 K | Citadel Advisors Llc | 2024-09-30 | 663.9 K | Spyglass Capital Management Llc | 2024-09-30 | 652.8 K | Fidelity International Ltd | 2024-09-30 | 640.3 K | Blackrock Inc | 2024-09-30 | 536.1 K | Millennium Management Llc | 2024-09-30 | 501.7 K | Ra Capital Management, Llc | 2024-09-30 | 9.7 M | Westfield Capital Management Company, L.p. | 2024-09-30 | 5.1 M |
Follow Ascendis Pharma's market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 7.66 B.Market Cap |
|
Project Ascendis Pharma's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.67) | (0.71) | |
| Return On Capital Employed | (0.83) | (0.79) | |
| Return On Assets | (0.67) | (0.70) | |
| Return On Equity | 3.80 | 3.99 |
When accessing Ascendis Pharma's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Ascendis Pharma's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Ascendis Pharma's profitability and make more informed investment decisions.
Please note, the presentation of Ascendis Pharma's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Ascendis Pharma's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Ascendis Pharma's management manipulating its earnings.
Evaluate Ascendis Pharma's management efficiency
Ascendis Pharma AS has return on total asset (ROA) of (0.2792) % which means that it has lost $0.2792 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (8.1843) %, meaning that it created substantial loss on money invested by shareholders. Ascendis Pharma's management efficiency ratios could be used to measure how well Ascendis Pharma manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Equity is expected to grow to 3.99, whereas Return On Tangible Assets are forecasted to decline to (0.71). At present, Ascendis Pharma's Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 848.5 M, whereas Non Current Assets Total are forecasted to decline to about 79.4 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (2.33) | (2.21) | |
| Tangible Book Value Per Share | (2.40) | (2.28) | |
| Enterprise Value Over EBITDA | (18.64) | (17.71) | |
| Price Book Value Ratio | (50.62) | (48.09) | |
| Enterprise Value Multiple | (18.64) | (17.71) | |
| Price Fair Value | (50.62) | (48.09) | |
| Enterprise Value | 6 B | 6.3 B |
Leadership effectiveness at Ascendis Pharma AS is a strong indicator of its financial stability. We analyze various metrics to provide insights into the stock's investment viability.
Enterprise Value Revenue 23.2182 | Revenue | Quarterly Revenue Growth (0.24) | Revenue Per Share | Return On Equity |
Ascendis Pharma Corporate Filings
6K | 15th of January 2025 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
| 20th of September 2024 Other Reports | ViewVerify | |
| 18th of September 2024 Other Reports | ViewVerify |
Ascendis Pharma Earnings Estimation Breakdown
The calculation of Ascendis Pharma's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Ascendis Pharma is estimated to be -1.731175 with the future projection ranging from a low of -1.9275 to a high of -1.43. Please be aware that this consensus of annual earnings estimates for Ascendis Pharma AS is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-1.93 Lowest | Expected EPS | -1.43 Highest |
Ascendis Pharma Earnings Projection Consensus
Suppose the current estimates of Ascendis Pharma's value are higher than the current market price of the Ascendis Pharma stock. In this case, investors may conclude that Ascendis Pharma is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Ascendis Pharma's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2024 | Current EPS (TTM) | |
| 15 | 76.57% | -1.72 | -1.731175 | -7.69 |
Ascendis Pharma Earnings History
Earnings estimate consensus by Ascendis Pharma AS analysts from Wall Street is used by the market to judge Ascendis Pharma's stock performance. Investors also use these earnings estimates to evaluate and project the stock performance into the future in order to make their investment decisions. However, we recommend analyzing not only Ascendis Pharma's upcoming profit reports and earnings-per-share forecasts but also comparing them to our different valuation methods.Ascendis Pharma Quarterly Gross Profit |
|
Ascendis Pharma Earnings per Share Projection vs Actual
Actual Earning per Share of Ascendis Pharma refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Ascendis Pharma AS predict the company's earnings will be in the future. The higher the earnings per share of Ascendis Pharma, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Ascendis Pharma Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Ascendis Pharma, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Ascendis Pharma should always be considered in relation to other companies to make a more educated investment decision.Ascendis Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Ascendis Pharma's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-11-05 | 2024-09-30 | -1.89 | -1.72 | 0.17 | 8 | ||
2024-09-03 | 2024-06-30 | -1.46 | -2.11 | -0.65 | 44 | ||
2024-05-02 | 2024-03-31 | -1.5 | -2.3 | -0.8 | 53 | ||
2024-02-07 | 2023-12-31 | -2.03 | -1.54 | 0.49 | 24 | ||
2023-11-07 | 2023-09-30 | -2.38 | -2.88 | -0.5 | 21 | ||
2023-09-05 | 2023-06-30 | -2.59 | -2.16 | 0.43 | 16 | ||
2023-04-27 | 2023-03-31 | -2.66 | -1.98 | 0.68 | 25 | ||
2023-02-16 | 2022-12-31 | -2.56 | -3.7 | -1.14 | 44 | ||
2022-11-02 | 2022-09-30 | -2.49 | -3.03 | -0.54 | 21 | ||
2022-08-10 | 2022-06-30 | -2.13 | -1.46 | 0.67 | 31 | ||
2022-05-11 | 2022-03-31 | -2 | -2.21 | -0.21 | 10 | ||
2022-03-02 | 2021-12-31 | -2.34 | -1.87 | 0.47 | 20 | ||
2021-11-10 | 2021-09-30 | -2.29 | -1.47 | 0.82 | 35 | ||
2021-08-25 | 2021-06-30 | -2.23 | -2.5 | -0.27 | 12 | ||
2021-05-27 | 2021-03-31 | -1.71 | -1.17 | 0.54 | 31 | ||
2021-03-10 | 2020-12-31 | -1.55 | -2.64 | -1.09 | 70 | ||
2020-11-11 | 2020-09-30 | -1.58 | -2.31 | -0.73 | 46 | ||
2020-08-27 | 2020-06-30 | -1.44 | -1.97 | -0.53 | 36 | ||
2020-05-19 | 2020-03-31 | -1.35 | -1.32 | 0.03 | 2 | ||
2019-12-31 | 2019-12-31 | -1.62 | -1.89 | -0.27 | 16 | ||
2019-11-18 | 2019-09-30 | -1.19 | -0.53 | 0.66 | 55 | ||
2019-08-28 | 2019-06-30 | -1.21 | -1.25 | -0.04 | 3 | ||
2019-05-30 | 2019-03-31 | -1 | -1.24 | -0.24 | 24 | ||
2018-12-31 | 2018-12-31 | -1.14 | -0.86 | 0.28 | 24 | ||
2018-11-28 | 2018-09-30 | -1.07 | -0.81 | 0.26 | 24 | ||
2018-08-29 | 2018-06-30 | -0.9 | -0.55 | 0.35 | 38 | ||
2018-05-30 | 2018-03-31 | -0.77 | -1.07 | -0.3 | 38 | ||
2018-03-28 | 2017-12-31 | -0.8 | -0.92 | -0.12 | 15 | ||
2017-11-16 | 2017-09-30 | -0.74 | -1.04 | -0.3 | 40 | ||
2017-08-18 | 2017-06-30 | -0.72 | -0.94 | -0.22 | 30 | ||
2017-05-23 | 2017-03-31 | -0.75 | -0.83 | -0.08 | 10 | ||
2017-03-22 | 2016-12-31 | -0.62 | -0.67 | -0.05 | 8 | ||
2016-11-30 | 2016-09-30 | -0.68 | -0.8 | -0.12 | 17 | ||
2016-08-31 | 2016-06-30 | -0.69 | -0.6 | 0.09 | 13 | ||
2016-04-14 | 2016-03-31 | -0.46 | -0.54 | -0.08 | 17 | ||
2015-11-12 | 2015-09-30 | -0.6 | -0.33 | 0.27 | 45 | ||
2015-08-24 | 2015-06-30 | -0.49 | -0.7 | -0.21 | 42 | ||
2015-05-18 | 2015-03-31 | -0.39 | 0.07 | 0.46 | 117 | ||
1899-12-31 | 1899-09-30 | -0.76 | -1.07 | -0.31 | 40 |
Ascendis Pharma Corporate Management
| Michael LLM | Chief VP | Profile | |
| Birgitte MD | Sr Affairs | Profile | |
| Stina MD | Executive Oncology | Profile | |
| Scott Holmes | Head Endocrinology | Profile | |
| Timothy Lee | Director Relations | Profile | |
| Nyssa Noyola | Vice Management | Profile | |
| Jens Okkels | VP Devel | Profile |
Already Invested in Ascendis Pharma AS?
The danger of trading Ascendis Pharma AS is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Ascendis Pharma is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Ascendis Pharma. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Ascendis Pharma AS is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Ascendis Pharma AS is a strong investment it is important to analyze Ascendis Pharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ascendis Pharma's future performance. For an informed investment choice regarding Ascendis Stock, refer to the following important reports: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Ascendis Pharma AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ascendis Pharma. If investors know Ascendis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ascendis Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (7.69) | Revenue Per Share | Quarterly Revenue Growth (0.24) | Return On Assets | Return On Equity |
The market value of Ascendis Pharma AS is measured differently than its book value, which is the value of Ascendis that is recorded on the company's balance sheet. Investors also form their own opinion of Ascendis Pharma's value that differs from its market value or its book value, called intrinsic value, which is Ascendis Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ascendis Pharma's market value can be influenced by many factors that don't directly affect Ascendis Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ascendis Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ascendis Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ascendis Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.